MENU

Epstein-Barr Virus Infections: Pay Me Now or Pay Me Later

Sponsored by: DiaSorin
Speaker
  • Professor of Pediatrics and Laboratory Medicine and Pathology, University of Minnesota
    Biography
      Dr. Balfour is Professor of Pediatrics in the Division of Infectious Diseases and Professor of Laboratory Medicine and Pathology. He also serves as Principal Investigator of Clinical Virology Programs. Dr. Balfour is recognized internationally as an expert in the diagnosis and treatment of herpesvirus infections, especially those due to EBV. Dr. Balfour received his MD degree from Columbia in 1966, completed his internship and residency at the University of Minnesota and Columbia-Presbyterian Medical Center in 1968, served as a pediatrician in the Air Force at Wright-Patterson Air Base, Dayton, OH from 1968-70, and then completed a post-doctoral fellowship in Infectious Disease at the University of Minnesota in 1972. He has been on the University of Minnesota faculty ever since. He is board certified in Pediatrics.

    Abstract

    Infectious mononucleosis has been recognized as a unique disease for more than 100 years and its cause, Epstein-Barr virus (EBV), was discovered more than 50 years ago.  Yet, there is no licensed vaccine and no clear-cut effective treatment for infections due to EBV. This webinar will explain why. We will cover: the clinical findings and laboratory tests for diagnosing and staging primary EBV infection; the mechanisms EBV uses to induce cancer and autoimmune diseases, especially multiple sclerosis; research approaches to prevention of EBV infection. Essentially all of us acquire EBV during our lifetime. Is it better to get it sooner or later? What do you think?

    Learning objectives:

    • At the conclusion of this webinar, you should be better able to:
    • Evaluate the clinical findings and laboratory tests used to diagnose EBV infection.
    • Discuss the probable mechanisms of EBV-spurred cancers and autoimmune disease.
    • Assess approaches to prevention of EBV infections.

    Show Resources
    You May Also Like
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    Loading Comments...
    Show Resources
    Attendees
    • See more